Neurocrine Biosciences, Inc. (N1BI34.SA) Stock Price, News & Chart

	N1BI34.SA	SUVEN.BO	0ND5.IL	ALKS	0QFP.IL	SUPN
Market cap	93.02B	63.96B	55.21B	7.71B	4.46T	1.64B
P/E (TTM)	26.1	—	22.4	—	18.8	—
Forward P/E	—	23.5	25.0	25.4	—	6.3
Price/book	4.8	21.8	2.6	4.1	2.1	-55.5
Dividend yield	—	—	1.58%	—	7.74%	—
1-year change	+10.78%	+30.58%	+20.02%	+44.85%	0.00%	−11.32%
Today	0.00%	−0.14%	+0.18%	+0.44%	+156.25%	+0.21%

Market cap

93.02B

63.96B

55.21B

7.71B

4.46T

1.64B

P/E (TTM)

26.1

—

22.4

—

18.8

—

Forward P/E

—

23.5

25.0

25.4

—

6.3

Price/book

4.8

21.8

2.6

4.1

2.1

-55.5

Dividend yield

—

1.58%

—

7.74%

—

1-year change

+10.78%

+30.58%

+20.02%

+44.85%

0.00%

−11.32%

Today

0.00%

−0.14%

+0.18%

+0.44%

+156.25%

+0.21%

Company	Mkt cap	Price	Today
Suven Life Sciences LimitedSUVEN.BO · Drug Manufacturers - Specialty & Generic	63.96B	275.75	−0.14%
H. Lundbeck A/S0ND5.IL · Drug Manufacturers - Specialty & Generic	55.21B	55.10	+0.18%
Alkermes plcALKS · Drug Manufacturers - Specialty & Generic	7.71B	45.89	+0.44%
Gedeon Richter PLC0QFP.IL · Drug Manufacturers - Specialty & Generic	4.46T	12,914.88	+156.25%
Supernus Pharmaceuticals, Inc.SUPN · Drug Manufacturers - Specialty & Generic	1.64B	28.21	+0.21%
Amylyx Pharmaceuticals, Inc.AMLX · Drug Manufacturers - Specialty & Generic	3.69B	29.40	+0.68%
BioCryst Pharmaceuticals, Inc.BCRX · Drug Manufacturers - Specialty & Generic	2.11B	8.24	−3.85%
iX Biopharma Ltd.42C.SI · Drug Manufacturers - Specialty & Generic	515.12M	0.4700	−3.09%

Company	Mkt cap	Price	Today
Zhejiang NHU Company Ltd.002001.SZ · Xinchang, China	82.52B	26.85	+1.94%
Suven Life Sciences LimitedSUVEN.NS · Hyderabad, India	78.02B	276.10	0.00%
Sinil Pharmaceutical Co., Ltd.012790.KQ · Chungju-si, South Korea	72.48B	6,270.00	0.00%
Daehan Nupharm Co.,Ltd.054670.KQ · Hwaseong-si, South Korea	71.58B	5,100.00	+0.20%
Kukje Pharma Co., Ltd.002720.KS · Seongnam-si, South Korea	70.36B	3,325.00	−1.63%
Aspen Pharmacare Holdings LimitedAPN.JO · Durban, South Africa	72.11B	16,657.00	+1.72%
High Tech Pharm Co., Ltd.106190.KQ · Chungju-si, South Korea	93.78B	8,820.00	−1.34%
Strides Pharma Science LimitedSTAR.NS · Bengaluru, India	92.87B	1,007.60	−0.65%

Company	Mkt cap	Price	Today
Zhejiang NHU Company Ltd.002001.SZ · Drug Manufacturers - Specialty & Generic	82.52B	26.85	+1.94%
Aier Eye Hospital Group Co., Ltd.300015.SZ · Medical Care Facilities	83.44B	8.99	+0.78%
Zhangzhou Pientzehuang Pharmaceutical Co., Ltd.600436.SS · Drug Manufacturers - General	81.65B	135.33	+2.39%
Moderna, Inc.0QF.F · Biotechnology	91.43B	229.00	+0.88%
Sanofi India LimitedSANOFI.BO · Drug Manufacturers - General	77.83B	3,379.40	+0.11%
Sanofi1SAN.MI · Drug Manufacturers - General	84.87B	70.84	−3.28%
CORESTEMCHEMON Inc.166480.KQ · Biotechnology	77.00B	1,601.00	−1.42%
Shofu Inc.7979.T · Medical Instruments & Supplies	76.94B	2,162.00	−0.23%

Company	Mkt cap	Price	Today
QUALCOMM IncorporatedQCOM · San Diego, CA	184.94B	173.19	+5.33%
Illumina, Inc.ILMN · San Diego, CA	34.25B	226.54	−4.90%
Realty Income CorporationO · San Diego, CA	56.04B	59.22	+2.99%
DexCom, Inc.DXCM · San Diego, CA	33.00B	88.48	+6.64%
SempraSRE · San Diego, CA	54.21B	82.90	−2.88%
ResMed Inc.RMD · San Diego, CA	33.83B	240.51	+5.91%
LPL Financial Holdings Inc.LPLA · San Diego, CA Odds	24.25B	311.48	+4.64%
Halozyme Therapeutics, Inc.HALO · San Diego, CA	14.79B	130.34	+1.34%

Company	Mkt cap	Price	Today
Ajanta Pharma LimitedAJANTPHARM.BO · devices · life sciences	410.04B	3,282.00	−0.95%
Tianjin Tianyao Pharmaceuticals Co., Ltd.600488.SS · devices · life sciences	5.47B	5.01	+1.83%
Sun Pharmaceutical Industries LimitedSUNPHARMA.BO · devices · life sciences	4.38T	1,825.35	+2.78%
Taiko Pharmaceutical Co.,Ltd.4574.T · devices · life sciences	13.38B	266.00	+1.14%
ChoA Pharmaceutical Co., LTD.034940.KQ · devices · life sciences	9.98B	1,610.00	0.00%
Kilitch Drugs (India) LimitedKILITCH.NS · devices · life sciences	7.29B	208.47	−0.21%
Hunan Er-Kang Pharmaceutical Co., Ltd300267.SZ · devices · life sciences	6.21B	3.0100	+2.03%
Strides Pharma Science LimitedSTAR.BO · devices · life sciences	92.73B	1,006.00	−0.58%

Company	Mkt cap	Price	Today
BIOMARIN PHADRNB1MR34.SA	55.80B	144.05	0.00%
THERMFISCHERDRNTMOS34.SA	1.43T	80.15	0.00%
NOVO NORDISKDRNN1VO34.SA	994.02B	28.18	−3.09%
ASCENDIS PHADRNA1SN34.SA	5.80B	88.11	0.00%
DEXCOM INCD1EX34.SA	175.85B	9.43	+3.29%

Seeking Alpha·4h agoPositive

Neurocrine Biosciences: Breaking Down A Solid Quarter

Neurocrine Biosciences posts strong Q3 earnings as INGREZZA drives growth and rare disease expansion gains traction. Find out why NBIX stock is a buy. - Neurocrine Biosciences delivered robust Q3 results Monday after the bell, with EPS of…

NBIX STIM

Seeking Alpha·22h agoPositive

Neurocrine Biosciences: 3 Growth Drivers And An Attractive Valuation

Neurocrine Biosciences offers growth and value with strong INGREZZA sales, new drug momentum, and 2027 catalysts. Learn more about NBIX stock here. - Neurocrine Biosciences is in an attractive growth phase, driven by strong INGREZZA sales…

NBIX NVO STIM

Seeking Alpha·22h agoPositive

Neurocrine Biosciences: Up 15% After Q3, And The Research Engine Is Still Almost Free

Neurocrine Biosciences remains a Buy as strong Q3 results and an underappreciated pipeline lift fair value. Read more on NBIX stock here. - Neurocrine Biosciences is reiterated as a buy with a new fair value of $195.80, 19% above the…

NBIX STIM LLY

Markets Daily·21h agoPositive

Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Target Raised at Guggenheim

Posted by Tristan Rich on Nov 4th, 2026 Neurocrine Biosciences (NASDAQ:NBIX – Get Free Report) had its price target boosted by investment analysts at Guggenheim from $207.00 to $224.00 in a report released on Wednesday, Benzinga reports.…

NBIX BIIB

TradingView·1d agoPositive

Canaccord Genuity maintains Neurocrine Biosciences at Buy, raises price target to $220 from $210

Canaccord Genuity maintained Neurocrine Biosciences at Buy and raised its price target to $220 from $210, a 4.8% increase. The price target implies an upside of 51.4% from the Nov 2 close of $145.35. Recent analyst actions on Neurocrine…

BIIB NBIX CADL

Pluang·22h agoPositive

Neurocrine Biosciences rated Buy with 19% upside on strong Q3 and undervalued research pipeline.

Neurocrine Biosciences is reaffirmed as a Buy with a new fair value of $195.80, representing a 19% increase from the recent price. The upgrade is driven by the company's strong Q3 results, with key drugs INGREZZA and CRENESSITY…

NBIX BIIB WFC

Neurocrine Biosciences·2d ago·2 outletsPositive

Neurocrine Biosciences Reports Third-Quarter 2026 Financial Results

Total Third-Quarter 2026 Revenue Grew 41% Year-Over-Year to $1.1 Billion INGREZZA® (valbenazine) 2026 Net Sales Guidance Raised to $2.9 to $2.925 Billion SAN DIEGO, Nov. 2, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX)…

NBIX CNSP ASPE

NEUROCRINE BIOSCIENCES ($NBIX) Releases Q3 2026 Earnings, Stock Rises

NEUROCRINE BIOSCIENCES ($NBIX) posted quarterly earnings results for Q3 2026 on Monday, November 2nd. The company reported earnings of $3.29 per share, beating estimates of $1.95 by $1.34. The company also reported revenue of…

NBIX NBIS NVDA MS

MarketScreener·2d agoPositive

Transcript : Neurocrine Biosciences, Inc., Q3 2026 Earnings Call, Nov 02, 2026

Presentation Operator MessageOperator Hello, and welcome, everyone joining today's Neurocrine Biosciences Third Quarter 2026 Earnings Call. [Operator Instructions] Please note this call is being... Transcript : Neurocrine Biosciences,…

SPCX GS

MarketScreener·2d agoPositive

Neurocrine Biosciences Presents 2-Year Results from Cahtalyst Pediatric and Cahtalyst Adult Studies of Crinecerfont

Published on 10/16/2026 at 01:50 pm EDT Neurocrine Biosciences, Inc. announced new real-world data demonstrating how the clinical and day-to-day impact of classic congenital adrenal hyperplasia can vary among individuals and evolve…

Days on the list

30 d

1 yr

Best

Trending

—

Install

Neurocrine Biosciences, Inc.

Key statistics

Against its peers

Latest news